Lifeloc Technologies Reports First Quarter 2024 Results
Lifeloc Technologies (OTC Pink:LCTC), a global leader in breath alcohol and drug testing devices, reported its financial results for Q1 2024. The company posted a net revenue of $2.153 million, with a net loss of $284,000, or $0.12 per share, compared to a net loss of $54,000, or $0.02 per share, in Q1 2023. Gross margins fell to 38.8% from 43.2% due to increased costs driven by inflation. R&D investments surged by 40%, primarily focused on the SpinDx platform development. Despite financial challenges, the company is optimistic about its new products, including the smartphone-compatible LX9 units and the SpinDx technology for drug detection. SpinDx, which detects various drugs including delta-9-THC, is expected to start beta testing in late 2024, with commercialization projected for 2025.
- Net revenue for Q1 2024 was $2.153 million.
- R&D investment rose by 40% focusing on SpinDx development.
- Positive market reception for LX9 and LT7 alcohol detection units.
- Smartphone pairing for LX9 units to be introduced in Q2 2024.
- SpinDx demonstrated effectiveness in detecting multiple drugs.
- Beta testing for SpinDx system expected later in 2024.
- Projected commercialization of SpinDx in 2025.
- Net loss of $284,000 for Q1 2024, increased from $54,000 in Q1 2023.
- Earnings per share (EPS) fell to -$0.12 from -$0.02 in Q1 2023.
- Gross margin declined to 38.8% from 43.2% due to inflation.
- Revenue change was essentially flat, with a decrease of $11,000.
WHEAT RIDGE, CO / ACCESSWIRE / May 15, 2024 / Lifeloc Technologies, Inc. (OTC Pink:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2024.
First Quarter Financial Highlights
Lifeloc posted quarterly net revenue of
We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. Additionally, smart phone pairing of the LX9 units is expected to be introduced in the second quarter of 2024.
"We are excited to be able to offer smart phone pairing with our LX9 units soon to achieve better systems integration, which some customers have been seeking," commented Dr. Wayne Willkomm, President and CEO.
We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains by the workplace Phoenix® 6.0 BT and EV 30 devices.
We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are therefore focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse. The initial product release is projected to be a device with a disk that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva, followed by a disk for a panel of other drugs. SpinDx has been demonstrated in our laboratory to effectively detect for delta-9-THC, cocaine, fentanyl, amphetamine methamphetamine, morphine, MDMA, and benzodiazepines. Testing has validated the SpinDx measurement technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data are validating the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness, speed, and convenience of operation. The start of beta testing of our SpinDx saliva testing system utilizing the delta-9-THC disks is expected later in 2024 using prototype readers as shown in the photograph below. Commercial launch of our first SpinDx application is projected to occur in 2025. Following initial commercialization, we expect more offerings from this technology platform to include expanded drug panels and samples collected from blood and breath. Following the release of our SpinDx saliva testing system, we expect to accelerate development of combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system.
"Our top priority is pushing the SpinDx product platform across the finish line," Dr. Willkomm said. "We anticipate increasing our research and development expenses in this final push toward commercialization. With the rising interest in saliva drug testing, the initial release of SpinDx to the market becomes more urgent and valuable."
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor .
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings .
Easycal® and Phoenix ® are registered trademarks of Lifeloc Technologies, Inc.
SpinDx™ is a trademark of Sandia Corporation.
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets
| ASSETS | ||||||||
| March 31, 2024 (Unaudited) | December 31, 2023 | |||||||
CURRENT ASSETS: | ||||||||
Cash | $ | 1,031,540 | $ | 1,766,621 | ||||
Accounts receivable, net | 756,907 | 812,126 | ||||||
Inventories, net | 3,017,505 | 3,024,834 | ||||||
Prepaid expenses and other | 266,956 | 105,967 | ||||||
Total current assets | 5,072,908 | 5,709,548 | ||||||
PROPERTY AND EQUIPMENT, at cost: | ||||||||
Land | 317,932 | 317,932 | ||||||
Building | 1,928,795 | 1,928,795 | ||||||
Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | ||||||
Production equipment, software and space modifications | 1,154,803 | 1,154,803 | ||||||
Training courses | 432,375 | 432,375 | ||||||
Office equipment, software and space modifications | 233,190 | 216,618 | ||||||
Sales and marketing equipment and space modifications | 226,356 | 226,356 | ||||||
Research and development equipment, software and space modifications | 522,542 | 480,684 | ||||||
Less accumulated depreciation | (3,375,026 | ) | (3,326,837 | ) | ||||
Total property and equipment, net | 2,010,415 | 2,000,174 | ||||||
OTHER ASSETS: | ||||||||
Patents, net | 84,327 | 64,439 | ||||||
Deposits and other | 265,169 | 111,157 | ||||||
Deferred taxes | 895,551 | 806,652 | ||||||
Total other assets | 1,245,047 | 982,248 | ||||||
Total assets | $ | 8,328,370 | $ | 8,691,970 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable | $ | 556,160 | $ | 402,231 | ||||
Term loan payable, current portion | 51,985 | 51,588 | ||||||
Income taxes payable | - | 44,952 | ||||||
Customer deposits | 178,052 | 195,719 | ||||||
Accrued expenses | 175,916 | 329,311 | ||||||
Deferred revenue, current portion | 76,247 | 79,036 | ||||||
Reserve for warranty expense | 46,500 | 46,500 | ||||||
Total current liabilities | 1,084,860 | 1,149,337 | ||||||
TERM LOAN PAYABLE, net of current portion and | ||||||||
debt issuance costs | 1,157,635 | 1,170,243 | ||||||
DEFERRED REVENUE, net of current portion | 8,856 | 11,565 | ||||||
Total liabilities | 2,251,351 | 2,331,145 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
STOCKHOLDERS' EQUITY: | ||||||||
Common stock, no par value; 50,000,000 shares | ||||||||
authorized, 2,454,116 shares outstanding | 4,668,014 | 4,668,014 | ||||||
Retained earnings | 1,409,005 | 1,692,811 | ||||||
Total stockholders' equity | 6,077,019 | 6,360,825 | ||||||
Total liabilities and stockholders' equity | $ | 8,328,370 | $ | 8,691,970 | ||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)
| Three Months Ended March 31, | ||||||||
REVENUES: | 2024 | 2023 | ||||||
Product sales | $ | 2,134,434 | $ | 2,133,359 | ||||
Royalties | 10,936 | 8,206 | ||||||
Rental income | 8,073 | 22,989 | ||||||
Total | 2,153,443 | 2,164,554 | ||||||
COST OF SALES | 1,318,136 | 1,229,127 | ||||||
GROSS PROFIT | 835,307 | 935,427 | ||||||
OPERATING EXPENSES: | ||||||||
Research and development | 555,599 | 396,766 | ||||||
Sales and marketing | 345,009 | 287,883 | ||||||
General and administrative | 314,926 | 319,015 | ||||||
Total | 1,215,534 | 1,003,664 | ||||||
OPERATING INCOME (LOSS) | (380,227 | ) | (68,237 | ) | ||||
OTHER INCOME (EXPENSE): | ||||||||
Interest income | 17,672 | 9,800 | ||||||
Interest expense | (10,150 | ) | (10,535 | ) | ||||
Total | 7,522 | (735 | ) | |||||
NET (LOSS) BEFORE PROVISION FOR TAXES | (372,705 | ) | (68,972 | ) | ||||
BENEFIT FROM FEDERAL AND STATE INCOME TAXES | 88,899 | 15,184 | ||||||
NET INCOME (LOSS) | $ | (283,806 | ) | $ | (53,788 | ) | ||
NET INCOME (LOSS) PER SHARE, BASIC | $ | (0.12 | ) | $ | (0.02 | ) | ||
NET INCOME (LOSS) PER SHARE, DILUTED | $ | (0.12 | ) | $ | (0.02 | ) | ||
WEIGHTED AVERAGE SHARES, BASIC | 2,454,116 | 2,454,116 | ||||||
WEIGHTED AVERAGE SHARES, DILUTED | 2,454,116 | 2,454,116 | ||||||
Lifeloc Technologies, Inc.
Condensed Statements of Stockholders' Equity (Unaudited)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Total stockholders' equity, beginning balances | $ | 6,360,825 | $ | 6,155,211 | ||||
Common stock (no shares issued during periods): | ||||||||
Beginning balances | 4,668,014 | 4,668,014 | ||||||
Ending balances | 4,668,014 | 4,668,014 | ||||||
Retained earnings: | ||||||||
Beginning balances | 1,692,811 | 1,487,197 | ||||||
Net (loss) | (283,806 | ) | (53,788 | ) | ||||
Ending balances | 1,409,005 | 1,433,409 | ||||||
Total stockholders' equity, ending balances | $ | 6,077,019 | $ | 6,101,423 | ||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)
| Three Months Ended March 31, | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | 2024 | 2023 | ||||||
Net (loss) | $ | (283,806 | ) | $ | (53,788 | ) | ||
Adjustments to reconcile net income to net cash | ||||||||
provided from (used in) operating activities- | ||||||||
Depreciation and amortization | 51,085 | 72,490 | ||||||
Provision for inventory obsolescence, net change | 17,500 | - | ||||||
Deferred taxes, net change | (88,899 | ) | (15,184 | ) | ||||
Changes in operating assets and liabilities- | ||||||||
Accounts receivable | 55,219 | 84,089 | ||||||
Inventories | (10,171 | ) | (130,416 | ) | ||||
Prepaid expenses and other | (160,989 | ) | (155,863 | ) | ||||
Deposits and other | (154,012 | ) | - | |||||
Accounts payable | 153,929 | 88,806 | ||||||
Income taxes payable | (44,952 | ) | - | |||||
Customer deposits | (17,667 | ) | (11,884 | ) | ||||
Accrued expenses | (153,395 | ) | (157,567 | ) | ||||
Deferred revenue | (5,498 | ) | (6,689 | ) | ||||
Net cash provided from (used in) | ||||||||
operating activities | (641,656 | ) | (286,006 | ) | ||||
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: | ||||||||
Purchases of property and equipment | (58,430 | ) | - | |||||
Patent filing expense | (21,708 | ) | (1,404 | ) | ||||
Net cash (used in) investing activities | (80,138 | ) | (1,404 | ) | ||||
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: | ||||||||
Principal payments made on term loan | (13,287 | ) | (12,900 | ) | ||||
Net cash provided from (used in) financing | ||||||||
activities | (13,287 | ) | (12,900 | ) | ||||
NET INCREASE (DECREASE) IN CASH | (735,081 | ) | (300,310 | ) | ||||
CASH, BEGINNING OF PERIOD | 1,766,621 | 2,352,754 | ||||||
CASH, END OF PERIOD | $ | 1,031,540 | $ | 2,052,444 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Cash paid for interest | $ | 9,073 | $ | 9,459 | ||||
Cash paid for income tax | $ | 6,440 | $ | - | ||||
SOURCE: Lifeloc Technologies, Inc.
View the original press release on accesswire.com
FAQ
What were Lifeloc Technologies' Q1 2024 earnings?
How did Lifeloc Technologies' revenue perform in Q1 2024?
What is the gross margin for Lifeloc Technologies in Q1 2024?
What are Lifeloc Technologies' plans for the SpinDx platform?
What new features will the Lifeloc LX9 units have?
